№ lp_2_2_02669
File format: docx Character count: 31123 File size: 75 KB
Year: 2025
Region / city: UK
Topic: Rheumatology, Axial Spondyloarthritis
Document type: Guideline
Organization / institution: British Society for Rheumatology
Author: Sizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, Max Yates, Joe Eddison, Antoni Chan, Nick Clarke, Nadia Corp, Charlotte Davis, Lambert Felix, Kalveer Flora, William J Gregory, Gareth T Jones, Christopher A Lamb, Helena Marzo-Ortega, Daniel J Murphy, Harry Petrushkin, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Danielle A Van Der Windt, Dale Webb, Zenas Z N Yiu, Karl Gaffney
Target audience: Health professionals, rheumatologists
Period of validity: Ongoing
Approval date: 2025
Date of changes: Not specified
Context: This is a clinical guideline for treating axial spondyloarthritis with biologic and targeted synthetic DMARDs.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Informed Consent for Emergency Use/Treatment with an Unapproved Drug / Biologic / Device 16.315 (HRP-506)
Note: Year
Subject: Emergency Use Treatment
Document Type: Informed Consent Form
Naas General Hospital PPPG Template (2019) - Pre-screening and Management of Patients with Inflammatory Bowel Disease on Biologic Medication
Year: 2019
Region / City: Naas General Hospital
Topic: Inflammatory Bowel Disease, Biologic Medication
Document Type: Policy
Author: Joanna Rea, Inflammatory Bowel Disease Clinical Nurse Specialist
Target Audience: IBD CNSp, Gastroenterology team, nursing staff administering biologic medication
Approval Date: 14th January 2020
Revision Date: January 2023
Version Number: 1
Supporting Evidence: Infliximab, Remicade, Vedolizumab, Adalimumab, Imraldi, Amgevita, Hulio, Golimumab, Ustekinumab
Purpose: Standardization of pre-screening and management of IBD patients requiring biologic treatment
Scope: Biologic screening, patient education, IBD CNSp, gastroenterology team, nursing staff
Objective(s): Ensure best practice for IBD patients on biologics
Outcome(s): Clarity for staff on safe and evidence-based care for IBD patients on biologics
Governance: IBD Working Group
Review Group: Not Applicable
Date of Approval: 14th January 2020
Date of Next Revision: January 2023
FedBizOpps Special Notice - Award of Contracts under Solicitation 36C10G18R0003 for Biologics and Biologic Implants
Year: 2018
Region / City: Fredericksburg, VA
Topic: Biologics, Contracting, Medical Supplies
Document Type: Contract Award Notice
Agency: U.S. Department of Veterans Affairs
Author: Not specified
Target Audience: Contractors, Veterans Affairs
Period of Action: From September 27, 2018
Approval Date: September 27, 2018
Date of Changes: Not specified
INTERACT Meeting Package for Biologic XY Development Program Submission to FDA
Year: 2026
Region / City: United States, Silver Spring, MD
Subject: Drug and Biologic Product Development
Document Type: Meeting Package
Organization / Institution: U.S. Food and Drug Administration (FDA)
Author: Sponsor Investigator, MD, Professor, Department of University of California, Los Angeles
Target Audience: FDA Reviewers, CBER/CDER Staff
Submission Date: 2026
Meeting Type: INTERACT
Product Name: Biologic XY
Product Description: Adenoviral vector expressing human cDNA with 1 and 2 region deletions
Proposed Indication: Treatment or prevention of specific disease or condition
Content Sections: Introduction, Product Development Summary, Purpose of Meeting, Specific Questions, Supporting Data, Proposed Agenda, Sponsor Attendees, Suggested Dates, Meeting Format, References
Persistence in treatment with TNF-alpha inhibitors in Spondyloarthritis: comparison between original and biosimilar drugs - a pilot study
Year: 2022
Region / city: Viseu Dão-Lafões
Topic: Spondyloarthritis, TNF-alpha inhibitors, Biosimilars, Treatment Efficacy, Safety
Document type: Research Study
Institution: Unidade Local de Saúde Viseu Dão-Lafões
Author: Inês Almeida, Liliana Saraiva, Miguel Tavares, Ana Teixeira, Maura Couto
Target audience: Healthcare professionals, researchers, rheumatologists
Period of validity: January 2010 - May 2022
Approval date: Not specified
Date of changes: Not specified
Spondyloarthritis Guideline: Review questions
Note: Year
Topic: Spondyloarthritis
Document Type: Guideline
Target Audience: Healthcare professionals
Topics: DMARDs Biologic spondyloarthritis